SYSTEMS GENETICS TO DETERMINE RISK OF DEVELOPING DIABETES COMPLICATIONS
Emeritus Professor Grant Morahan, Professor of Diabetes Research, University of Western Australia Centre for Medical Research (affiliated with the Harry Perkins Institute of Medical Research), Perth, Australia & Honorary Professor, Baker Department of Cardiometabolic Health, University of Melbourne, Australia
RESEARCHER PROFILE
Filmed in Perth, Australia | December 2025
Professor Morahan invented the term “Systems Genetics” for the science field that examines how genetic variants can affect whole networks of genes and whole systems; there are now several laboratories and institutes of systems genetics around the world. He also developed the next-generation genetic resource, The Gene Mine, the most powerful of its type in the world, used globally in rapid mapping and identification of genes. Collaborators nationally and internationally have tested The Gene Mine for traits and diseases in which they specialise.
As a member of the Steering Committee of the Type 1 Diabetes Genetics Consortium, he worked to design the global study recruiting and characterising T1D genetics, which resulted in identification of over 40 T1D risk genes. The culmination of this program, for which Prof Morahan was PI of the Asia-Pacific Network, was published in Nature Genetics (41:703-707) and has been cited 1579 times.
Currently, he is a member of the Steering Committee of the Environmental Determinants of Islet Autoimmunity (ENDIA) Study, the only study in the world investigating T1D families to follow at-risk babies from pregnancy through childhood. Completing recruitment in 2020, the study already has 40 publications.
His latest discovery involves next-generation algorithms that are able to predict whether a person will be genetically high/low risk of developing a number of complex genetic diseases. Professor Morahan is working toward commercialising these genetic tests so they can benefit the public and the healthcare system.
During his career, Prof Morahan has supervised 23 postgraduate students and mentored nine postdoctoral positions. Since 2003, Prof Morahan has applied for and received close to $20 million in research funds, both nationally and internationally. He has 299 academic publications, 17,0744 citations and has an h-index of 60.
Source: Supplied
https://orcid.org/0000-0002-8562-7325
-
Non-invasive tools for CVD screening and monitoring
Dr Hadi Afsharan is a Research Fellow Cardiovascular Science & Diabetes at the Harry Perkins Institute of Medical Research; is a translational research and innovation fellow in medical technologies at The University of Western Australia, holding dual titles as Translational Fellow and Innovation Fellow within UWA’s Medical School and the FHRI (Future Health Research and Innovation) program.
-
Applying nanotechnology to chronic pain management
Dr Felicity Han is a Research Fellow and Leader in Pain Relief Innovation, at the Australian Institute for Bioengineering and Nanotechnology in the University of Queensland. Dr Han’s research interests sit at the interface of drug delivery and the pain field. Her overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management.
-
Neonatal respiratory trials in sick & preterm newborn infants
Prof Brett J. Manley leads and collaborates on large national and international randomised clinical trials in neonatology. He previously collaborated on 4 randomised trials of nasal high-flow as non-invasive respiratory support for preterm and term infants, all of which were published in N Engl J Med. Recently he led the PLUSS trial of intratracheal budesonide for extremely preterm infants, that recruited in 21 NICUs across 4 countries, the results of which were published in JAMA. PLUSS was awarded the Australian Clinical Trials Alliance Trial of the Year in 2025. Another passion of his is mentoring and supervising early career researchers to undertake their own clinical trials.
